196 related articles for article (PubMed ID: 31096572)
1. Massively Parallel Profiling of HIV-1 Resistance to the Fusion Inhibitor Enfuvirtide.
Dingens AS; Arenz D; Overbaugh J; Bloom JD
Viruses; 2019 May; 11(5):. PubMed ID: 31096572
[TBL] [Abstract][Full Text] [Related]
2. Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolates.
Baatz F; Nijhuis M; Lemaire M; Riedijk M; Wensing AM; Servais JY; van Ham PM; Hoepelman AI; Koopmans PP; Sprenger HG; Devaux C; Schmit JC; Perez Bercoff D
PLoS One; 2011; 6(7):e21535. PubMed ID: 21760896
[TBL] [Abstract][Full Text] [Related]
3. Mutations of Glu560 within HIV-1 Envelope Glycoprotein N-terminal heptad repeat region contribute to resistance to peptide inhibitors of virus entry.
Yuan C; Wang JY; Zhao HJ; Li Y; Li D; Ling H; Zhuang M
Retrovirology; 2019 Dec; 16(1):36. PubMed ID: 31796053
[TBL] [Abstract][Full Text] [Related]
4. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
Su Y; Chong H; Qiu Z; Xiong S; He Y
J Virol; 2015 Jun; 89(11):5801-11. PubMed ID: 25787278
[TBL] [Abstract][Full Text] [Related]
6. Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site.
Heil ML; Decker JM; Sfakianos JN; Shaw GM; Hunter E; Derdeyn CA
J Virol; 2004 Jul; 78(14):7582-9. PubMed ID: 15220433
[TBL] [Abstract][Full Text] [Related]
7. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.
Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
Antimicrob Agents Chemother; 2004 Sep; 48(9):3253-9. PubMed ID: 15328081
[TBL] [Abstract][Full Text] [Related]
8. Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.
Zhu Y; Chong H; Yu D; Guo Y; Zhou Y; He Y
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867304
[TBL] [Abstract][Full Text] [Related]
9. Peptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009 - 2014).
Zhang D; Li W; Jiang S
Expert Opin Ther Pat; 2015 Feb; 25(2):159-73. PubMed ID: 25428639
[TBL] [Abstract][Full Text] [Related]
10. HIVfird: A Tool for Detection of Resistance to Fusion Inhibitor Drugs in HIV-1 Sequences.
Barreto Vasconcelos AL; Monteiro-Cunha JP
AIDS Res Hum Retroviruses; 2019 Oct; 35(10):941-947. PubMed ID: 31280582
[TBL] [Abstract][Full Text] [Related]
11. Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev.
Svicher V; Alteri C; D'Arrigo R; Laganà A; Trignetti M; Lo Caputo S; Callegaro AP; Maggiolo F; Mazzotta F; Ferro A; Dimonte S; Aquaro S; di Perri G; Bonora S; Tommasi C; Trotta MP; Narciso P; Antinori A; Perno CF; Ceccherini-Silberstein F
Antimicrob Agents Chemother; 2009 Jul; 53(7):2816-23. PubMed ID: 19124665
[TBL] [Abstract][Full Text] [Related]
12. Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46.
Hermann FG; Egerer L; Brauer F; Gerum C; Schwalbe H; Dietrich U; von Laer D
J Virol; 2009 May; 83(10):4844-53. PubMed ID: 19279116
[TBL] [Abstract][Full Text] [Related]
13. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
Labrosse B; Morand-Joubert L; Goubard A; Rochas S; Labernardière JL; Pacanowski J; Meynard JL; Hance AJ; Clavel F; Mammano F
J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
[TBL] [Abstract][Full Text] [Related]
14. Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains.
Roman F; Gonzalez D; Lambert C; Deroo S; Fischer A; Baurith T; Staub T; Boulmé R; Arendt V; Schneider F; Hemmer R; Schmit JC
J Acquir Immune Defic Syndr; 2003 Jun; 33(2):134-9. PubMed ID: 12794544
[TBL] [Abstract][Full Text] [Related]
15. Virological fitness of HIV in patients with resistance to enfuvirtide.
Chibo D; Roth N; Roulet V; Skrabal K; Gooey M; Carolan L; Nicholls J; Papadakis A; Birch C
AIDS; 2007 Sep; 21(14):1974-7. PubMed ID: 17721108
[TBL] [Abstract][Full Text] [Related]
16. Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-resistant HIV-1 gp41 hairpin structure.
Jenwitheesuk E; Samudrala R
Antivir Ther; 2005; 10(8):893-900. PubMed ID: 16430194
[TBL] [Abstract][Full Text] [Related]
17. Resistance to enfuvirtide, the first HIV fusion inhibitor.
Greenberg ML; Cammack N
J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
[TBL] [Abstract][Full Text] [Related]
18. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
[TBL] [Abstract][Full Text] [Related]
19. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy.
Poveda E; Rodés B; Lebel-Binay S; Faudon JL; Jimenez V; Soriano V
J Clin Virol; 2005 Dec; 34(4):295-301. PubMed ID: 16286053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
